ESG risk score 33.27
Environmental score -
Social score -
Governance score -
ESG risk category High
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Infant Bacterial Therapeutics AB
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol IBT_B:xome
Currency SEK
NASDAQ OMX Stockholm
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) -2.18%
1 year 18.47%
3 years 4.5%
Data provided by 
Key stats
Price/earnings (LTM) -
Dividend yield (LTM) -
EPS (LTM) -4.84
Volatility (30 days) -
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
Sector Healthcare
Industry -
Market cap 0.653362076bn
Data provided by /
/ Frequently asked questions
To buy Infant Bacterial Therapeutics AB stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Infant Bacterial Therapeutics AB by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Infant Bacterial Therapeutics AB is IBT_B:xome. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Infant Bacterial Therapeutics AB has its primary listing on NASDAQ OMX Stockholm. You can trade Infant Bacterial Therapeutics AB with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Infant Bacterial Therapeutics AB is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Infant Bacterial Therapeutics AB as part of a broader investment portfolio.